Business Context and Reporting Period
This Form 8-K Current Report from Innventure, Inc. (INV) covers events occurring on April 29, 2026, and April 30, 2026. The filing addresses significant changes to the composition of the Board of Directors and the resulting impact on the company's compliance with Nasdaq listing standards.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status rather than financial performance.
Material Changes
- Board Resignation: Daniel Hennessy resigned from the Board of Directors and all committees, including the Audit Committee, effective April 29, 2026.
- Nasdaq Noncompliance: The resignation reduced the Audit Committee to two members, rendering the company noncompliant with Nasdaq Listing Rule 5605(c)(2)(A), which requires a minimum of three members.
- Board Appointment: John Hewitt was appointed to the Board effective April 29, 2026, to fill the vacancy left by Mr. Hennessy. His committee assignments have not yet been determined.
- Director Nomination: Catriona Fallon was nominated to stand for election as a Board member at the 2026 Annual Meeting of Stockholders scheduled for June 17, 2026.
Outlook, Risks, and Contingencies
- Cure Period: The company has an automatic cure period under Nasdaq Listing Rule 5606(c)(4)(B) to regain compliance, expiring on October 26, 2026.
- Compliance Plan: Management expects to regain compliance by appointing an additional qualifying director to the Audit Committee before the cure period expires.
- Resignation Context: The company stated that Mr. Hennessy's resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
Investor Verification Checklist
- Verify the specific committee assignments for the newly appointed director, John Hewitt, to confirm if the Audit Committee will be restored to three members immediately.
- Monitor the company's progress toward appointing a third Audit Committee member before the October 26, 2026, deadline to avoid potential delisting.
- Review the Definitive Proxy Statement for the 2026 Annual Meeting for details on the nomination of Catriona Fallon and the non-management director compensation program.
- Confirm the independence status of the current and proposed Audit Committee members to ensure full compliance with Nasdaq rules.